AQST Q1 2025 Earnings — Aquestive Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AQSTAquestive Therapeutics, Inc.

$431M

Q1 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$9M-27.7% YoY

Gross Profit

$5M58.1% margin

Operating Income

-$19M-222.1% margin

Net Income

-$23M-263.0% margin

EPS (Diluted)

$-0.24

QoQ Revenue Growth

-26.5%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$24M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$102M

Total Liabilities

$163M

Stockholders' Equity

-$61M

Cash & Equivalents

$69M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$12M	-27.7%
Gross Profit	$5M	$8M	-33.9%
Operating Income	-$19M	-$9M	-116.2%
Net Income	-$23M	-$13M	-78.7%

Revenue Segments

Manufacture and Supply Revenue

$7M82%

License and Royalty Revenue

$790,0009%

Co-Development and Research Fees

$418,0005%

Manufactured Product, Other

$319,0004%

Geographic Segments

UNITED STATES

$5M60%

Non-US

$4M40%